Reactive oxygen species and the neurodegenerative disorders

Annals of Clinical and Laboratory Science

Volumn 27, Issue 1, 1997, Pages 11-25

  Knight, Joseph A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN ISCHEMIA; DEGENERATIVE DISEASE; DOWN SYNDROME; DRUG BLOOD LEVEL; ENCEPHALOMYOPATHY; HUMAN; MULTIPLE SCLEROSIS; PARKINSON DISEASE; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW;

AGING; ANTIOXIDANTS; HUMANS; ISCHEMIA; LIPID PEROXIDATION; MACROPHAGES; MITOCHONDRIAL ENCEPHALOMYOPATHIES; NERVOUS SYSTEM DISEASES; NITRIC OXIDE; REACTIVE OXYGEN SPECIES;

EID: 0031031920     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Ravindranath V, Shivakumar BR, Anandatheerthavarada HK. Low glutathione levels in brain regions of aged rats. Neurosci Lett 1989;101:187-90.
2. Cohen G, Oxygen radicals and Parkinson's disease. In: Halliwell B, ed, Oxygen Radicals and Tissue Injury. FASEB 1988:130-5.
3. Stocks J, Gutteridge JMC, Sharp RJ, Dormandy TL. The inhibition of lipid peroxidation by human serum and its relationship to serum proteins and alpha-tocopherol. Clin Sci 1974;47:223-33.
4. Poulin JE, Cover C, Gustafson MR, Kay MMB. Vitamin E prevents oxidative modification of brain and lymphocyte band 3 proteins during aging. Proc Natl Acad Sci USA 1996;93:5600-3.
5. Halliwell B. Oxidants and the central nervous system: some fundamental questions. Acta Neurol Scand 1989;126:23-33.
6. Jenner P. Oxidative damage in neurodegenerative disease. Lancet 1994;344:796-8.
7. Snyder SH. Nitric oxide: First in a new class of neurotransmitters? Science 1992;257:494-6.
8. Van der Vliet A, Smith D, O'Neill CA, et al. Interactions of peroxynitrite with human plasma and its constituents: oxidative damage and antioxidant depletion. Biochem J 1994;303:295-301.
9. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral ,sclerosis. Nature 1993;362:59-62.
10. Deng H-X, Hentati A, Tainer JA, et al. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science 1993;261:1047-51.
11. Rosen DR, Bowling AC, Patterson D, et al. A frequent ala4 to val superoxide dismutase-1 mutation is associated with a rapidly progressive familial amyotrophic lateral sclerosis. Hum Mol Genet 1994;3:981-7.
12. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994;264: 1772-5.
13. Brown RH. Clinical implications of basic research: A transgenic-mouse model of amyotrophic lateral sclerosis. N Engl J Med 1994;331:1091-2.
14. Beckman JS, Carson M, Smith CD, Koppenol WH. ALS, SOD and peroxynitrite. Nature 1993;364:584.
15. Katzman R. Alzheimer's disease. N Engl J Med 1986; 314:964-73.
16. West MJ, Coleman PD, Flood DG, Troncoso JC. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet 1994;344:769-72.
17. Jeandel C, Nicolas MB, Dubois F, et al. Lipid peroxidation and free radical scavengers in Alzheimer's disease. Gerontology 1989;35:275-82.
18. Heyman A, Wilkinson WE, Hurwitz BJ, et al. Alzheimer's disease: Genetic aspects and associated clinical disorders. Ann Neurol 1983;14:507-15.
19. Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 1985;17:278-82.
20. Volicer L, Crino PB. Involvement of free radicals in dementia of the Alzheimer type: A hypothesis. Neurobiol Aging 1990;11:567-71.
21. St George-Hyslop PH, Tanzi RE, Polinsky RJ, et al. The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science 1987;235:885-90.
22. Hensley K, Carney JM, Mattson MP, et al. A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer's disease. Proc Natl Acad Sci USA 1994;91: 3270-4.
23. Smith CD, Carney JM, Starke-Reed PE, et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer's disease. Proc Natl Acad Sci USA 1991;88:10540-3.
24. McNamara JO, Fridovich I. Did radicals strike Lou Gehrig? Nature 1993;363:20-1.
25. Sohal RS, Wolfe LS. Lipofuscin: characteristics and significance. Prog Brain Res 1986;70:171-83.
26. Dowson JH. Neuronal lipofuscin accumulation in ageing and Alzheimer's dementia: a pathogenic mechanism? Br J Psychiatr 1982;140:142-8.
27. Westermarck T, Santavuori P, Heiskala H. Antioxidant therapy in neuronal ceroid lipofuscinosis (NCL). In; Miquel J, Quintanilha AT, Weber H, eds. CRC Handbook of Free Radicals and Antioxidants in Biomedicine, Vol II. Boca Raton, Florida: CRC Press, 1989:281-7.
28. Evans PH. Free radicals in brain metabolism and pathology. Br Med Bull 1993;49:577-87.
29. Pappolla MA, Omar RA, Kim KSA, Robakis NK. Immunohistochemical evidence of antioxidant stress in Alzheimer's disease. Am J Pathol 1992;140:621-8.
30. Behl C, Davis J, Cole CM, Schubert D. Vitamin E protects nerve cells from amyloid beta protein toxicity. Biochem Biophys Res Comm 1992;186:944-50.
31. Zaman Z, Roche S, Fielden P, et al. Plasma concentrations of vitamins A and E and carotenoids in Alzheimer's disease. Age Ageing 1992;21:91-4.
32. Schneider EL, Epstein CJ, Replication rate and lifespan of cultured fibroblasts in Down's syndrome. Proc Soc Exp Biol Med 1972;141:1092-4.
33. Sinet PM. Metabolism of oxygen derivatives in Down's syndrome. Ann NY Acad Sci 1982;396:83-94.
34. Kedziora J, Bartosz G. Down's syndrome: A pathology involving the lack of balance of reactive oxygen species. Free Rad Biol Med 1988;4:317-30.
35. Fried R, Fried LW, Babin DR. Biological role of xanthine oxidase and tetrazolium-reductase inhibitor. Eur J Biochem 1973;33:439-45.
36. Antila E, Westermarck T. On the etiopathogenesis and therapy of Down's syndrome. Int J Dev Biol 1989; 33:183-8.
37. Schoenberg BS, Anderson DW, Haerer AF. Prevalence of Parkinson's disease in the biracial population of Copiah County, Mississippi. Neurology 1985;35: 841-5.
38. Poirer J, Kogan S, Gauthier S. Environment, genetics and idiopathic Parkinson's disease. Canad J Neurol Sci 1991; 18:70-6.
39. Barbeau A. Etiology of Parkinson's disease: a research strategy. Can J Neurol Sci 1984;11:24-8.
40. Calne DB. Aetiology of Parkinson's disease. Lancet 1983;2:1457-9.
41. Marsden CD. Parkinson's disease. Lancet 1990;335: 948-53.
42. Lieberman A, Emerging perspectives in Parkinson's disease. Neurology 1992;42(suppl 4):5-7.
43. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989;52:381-9.
44. Ambani IM, VanWoert MH, Murphy S. Brain peroxidase and catalase in Parkinson's disease. Arch Neurol 1975;32:114-8.
45. Perry TL, Godin DV, Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 1982;33:305-10.
46. Schapira AHV, Cooper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990;54:823-7.
47. Fahn S. High-dosage antioxidants in early Parkinson's disease. Arch Neurol 1988;45:810 (abstract).
48. Golbe LI, Farrell TM, Davis PH. Case-control study of early life dietary factors in Parkinson's disease. Arch Neurol 1988;45:1350-3.
49. Birkmayer W, Knoll J, Reiderer P, et al. Increased life expectancy resulting from addition of L-deprenyl to Madopar® treatment in Parkinson's disease: a long-term study. J Neurol Transm 1985;64:113-27.
50. Parkinson's Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-71.
51. Hallgren B, Sourander P. The effect of age on the nonhaemin iron in human brain. J Neurochem 1958; 3:41-51.
52. Dexter DT, Wells FR, Agid F, et al. Increased nigral iron content in postmortem parkinsonian brain. Lancet 1987;2:1219-20.
53. Dexter DT, Wells FR, Lees AJ, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 1989;52:1830-6.
54. Sian J, Dexter DT, Lees AJ, et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting the basal ganglia. Ann Neurol 1994;36:348-55.
55. Spina MB, Cohen G. Dopamine turnover and glutathione oxidation: Implications for Parkinson's disease. Proc Natl Acad Sci USA 1989;86:1398-1400.
56. Spina MB, Cohen G. Exposure of school synaptosomes to L-dopa increases levels of oxidized glutathione. J Pharm Exp Ther 1988;247:502-7.
57. Adams JD, Odunze IN. Oxygen free radicals and Parkinson's disease. Free Rad Biol Med 1991;10:161-9.
58. Graham DG. On the origin and significance of neuromelanin. Arch Pathol Lab Med 1979; 103:359-62.
59. Phebus LA, Perry KW, Clemens JA, Fuller RW. Brain anoxia releases striatal dopamine in rats. Life Sci 1986; 38:2447-53.
60. Clemens JA, Phebus LA. Dopamine depletion protects striatal neurons from ischemia-induced cell death. Life Sci 1988;42:707-13.
61. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-80.
62. Odunze IN, Klaidman LK, Adams JD. MPTP toxicity in the mouse brain and vitamin E. Neurosci Lett 1990; 108:346-19.
63. Adams JD, Odunze IN, Sevanian A. Induction by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of lipid peroxidation in vivo in vitamin E deficient mice. Biochem Pharmacol 1990;39:R5-R8.
64. Snyder SH, D'Amato RJ. MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. Neurology 1986;36:250-8.
65. Couper J. On the effects of black oxide of manganese when inhaled into the lungs. Br Ann Med Pharmac 1837:1:41-2.
66. Cotzias GC. Manganese, melanins and the extrapyramidal system. J Neurosurg 1966;24:170-80.
67. Donaldson J, LaBella FS, Gesser D. Enhanced autooxidation of dopamine as possible basis of manganese neurotoxicity. Neurotoxicology 1981;1:53-64.
68. Canavan MM, Drinker CK. Chronic manganese poisoning. Report of a case with autopsy. Arch Neurol Psychiatr 1934;32:501-13.
69. Raine CS. Demyelinating diseases. Textbook of Neuropathology. 2nd ed., Davis RL, Robertson DM, eds., Baltimore: Williams and Wilkins, 1991:535.
70. Bowern N, Ramshaw IA, Clark IA, Doherty PC. Inhibition of autoimmune neuro-pathological process by treatment with an iron chelating agent. J Exp Med 1984;160:1532-43.
71. Le Vine SM. The role of reactive oxygen species in the pathogenesis of multiple sclerosis. Med Hypotheses 1992;39:271-4.
72. Korpela H, Kinnunen E, Juntunen J, et al. Serum selenium concentration, glutathione peroxidase activity and lipid peroxides in a co-twin control study on multiple sclerosis. J Neurol Sci 1989;91:79-84.
73. Toshniwal PK, Zarling EJ. Evidence for increased lipid peroxidation in multiple sclerosis. Neurochem Res 1992;17:205-7.
74. Konat GW, Wiggins RC. Effect of reactive oxygen species on myelin membrane proteins. J Neurochem 1985;45:1113-8.
75. Ebers GC, Sadovniek AD, Risch NJ and the Canadian Collaborative Study Group. Familial aggregation in multiple sclerosis is genetic. Nature 1995;377:150-1.
76. Sadovniek AD, Ebers GC, Dyment DA, et al. Evidence for a genetic basis of multiple sclerosis. Lancet 1996;347:1728-30.
77. Hachinski V. Preventable senility: a call for action against the vascular dementias. Lancet 1992;340: 645-8.
78. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 1989;262:2551-6.
79. Watson BD, Ginsberg MD. Mechanisms of lipid peroxidation potentiated by ischemia in the brain. In: Halliwell B, ed., Oxygen Radicals and Tissue Injury FASEB, 1988:81-91.
80. Hall ED, Braughler JM. The role of oxygen radical-induced lipid peroxidation in acute nervous system trauma. In: Halliwell B, ed., Oxygen Radicals and Tissue Injury. FASEB, 1988:92-8.
81. Willmore LJ, Ballinger WE, Boggs W, et al. Dendritic alterations in rat isocortex within an iron-induced chronic epileptic focus. Neurosurgery 1980;7:142-6.
82. Davalos A, Fernandez-Real JM, Ricart W, et al. Iron-related damage in acute ischemic stroke. Stroke 1994; 25:1543-6.
83. Flamm ES, Demopoulos HB, Seligman ML, et al. Radicals in cerebral ischemia. Stroke 1978;9:445-7.
84. Traystman RJ, Kirsch JR, Koehler RC. Oxygen radical mechanisms of brain injury following ischemia and reperfusion. J Appl Physiol 1991;71:1185-95.
85. McCord JM. Oxygen-derived free radicals In post ischemic tissue injury. N Engl J Med 1985;312:159-63.
86. Patt A, Harken AH, Burton LK, et al. Xanthine oxidase-derived hydrogen peroxide contributes to ischemia reperfusion-induced edema in gerbil brains. J Clin Invest 1988;81:1556-62.
87. Itoh T, Kawakami M, Yamauchi Y, et al. Effect of allopurinol on ischemia and reperfusion-induced cerebral injury in spontaneously hypertensive rats. Stroke 1986;17:1284-7.
88. Patt A, Horesh IR, Berger EM, et al. Iron depletion or chelation reduces ischemia/reperfusion-induced edema in gerbil brains. J Pediatr Surg 1990;25:224-8.
89. DiMauro S, Moraes CT. Mitochondrial encephalopathies. Arch Neurol 1993;50:1197-1208.
90. Johns DR. Mitochondrial DNA and disease. N Engl J Med 1995;333:638-44.
91. Stephenson J. A role for mitochondria in age-related disorders? JAMA 1996;275:1531-2.
92. Linnane AW, Marzuki S, Ozawa T, Tanaka M. Mitochondrial DNA mutations as an important contributor to ageing and degenerative diseases. Lancet 1989;1: 642-5.
93. Wallace DC. Mitochondrial genetics: A paradigm for aging and degenerative diseases? Science 1992;256: 628-32.